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Abstract
Multiple new recommendations have been introduced in the 2020 ESC guidelines for the management of acute coronary
syndromes with a focus on diagnosis, prognosis, and management of patients presenting without persistent ST-segment
elevation. Most recommendations are supported by high-quality scientific evidence. The guidelines provide solutions to overcome obstacles presumed to complicate a convenient interpretation of troponin results such as age-, or sex-specific cutoffs,
and to give practical advice to overcome delays of laboratory reporting. However, in some areas, scientific support is less
well documented or even missing, and other areas are covered rather by expert opinion or subjective recommendations. We
aim to provide a critical appraisal on several recommendations, mainly related to the diagnostic and prognostic assessment,
highlighting the discrepancies between Guideline recommendations and the existing scientific evidence.
Keywords Guidelines · Critical appraisal · Acute coronary syndromes · Non-ST-segment elevation · High-sensitivity
troponin · Diagnosis · Prognosis · Management
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Introduction
In August 2020, the European Society of Cardiology (ESC)
presented the Guidelines on NSTE-ACS during the Annual
Congress that was held on a virtual platform [1]. These
2020 Guidelines introduced new and revised sections on
important topics that differ from the preceding 2015 ESC
Guidelines on NSTE-ACS [2]. We believe that some of the
new recommendations, which can be anticipated to influence medical decision-making, were not supported by an
appropriate level of evidence and are worth reconsidering.
As a global phenomenon, the diagnosis of acute myocardial infarction (AMI) has remained challenging and still
chest pain and/or dyspnea are amongst the most prevalent
symptoms leading to emergency department (ED) admission
in the USA [3]. Accordingly, many EDs face overcrowding as the numbers of patients seeking medical attention for
unspecific chest pain are steadily increasing while numbers
of patients with confirmed NSTE-ACS have remained stable
or are slightly decreasing [4]. Acceleration of patient disposition and facilitation of safe and early discharge have been
identified as pragmatic solutions to decongest busy EDs [5].
Therefore, the rationale to advance the use of hs-cTn assays
and to further instigate the implementation of faster diagnostic algorithms has to be appreciated. Moreover, guidelines endorse measures for a more convenient, user-friendly
interpretation of cTn results such as the recommendation
to abstain from age-, sex-, or comorbidity-adapted decision
cutoffs although the use of sex-specific cutoffs has been
endorsed by the 4th version of the Universal Definition of
Myocardial Infarction (UDMI). Other practical recommendations are given to overcome infrastructural barriers in the
hospitals such as delayed laboratory reporting.
Therefore, this expert opinion article highlights strengths
of the 2020 ESC NSTE-ACS Guidelines but also indicates
limitations, where the recommendations are open to question
in the light of inconsistent or absent evidence.

Critical appraisal of the guidelines
Strengths of 2020 ESC guidelines
Overall, the guideline authors must be congratulated for
creating an extensive and comprehensive update of the preceding 2015 ESC Guidelines on acute coronary syndromes
[2] without ST-segment elevations (NSTE-ACS). As a consequence of the accumulated evidence regarding the efficacy and safety of accelerated diagnostic protocols, new
recommendations were introduced regarding the diagnostic
strategies.
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ESC 0/1 h protocol endorsed as the preferential diagnostic
strategy
While the 2011 ESC [6] and 2015 ESC guidelines [2]
endorsed the ESC 0/3 h protocol whenever hs-cTn assay
were available in clinical routine, the 2020 ESC guidelines
[1] now recommend to use the ESC 0/1 h protocol preferentially over the ESC 0/3 h protocol. Supportive evidence
comes from several independent observational studies, a
randomized controlled trial (RCT) from Australia [7], two
real-world evidence studies [8, 9], and a meta-analysis from
15 trials that include 11,014 patients [10] that have conferred
robust evidence on efficacy and safety of the ESC 0/1 h protocol. Besides the excellent discriminatory ability to rule
out a NSTEMI, findings corroborate the safety of discharge
after rule out of patients deemed to be at low risk [7–10].
One study shows higher discharge rates without increased
utilization of coronary angiography, coronary interventions,
cardiac stress, or imaging procedures [11]. The promotion
of the ESC 0/1 h algorithm is further fostered by findings on
reduced length of observation time and overall length of stay
in ED, and lower hospital costs [12]. However, in the past,
concerns were also expressed regarding the universal use of
the ESC 0/1 h algorithm, mainly based on doubts regarding
the accuracy of very small concentration changes, the limited evidence on early presenters, and uncertainties about
the accuracy of rule-in using short re-testing intervals [13].
In full awareness that fast protocols are adopted slower than
projected [14], the authors suggested solutions to overcome
laboratory delays from blood draw to reporting, an issue presumed to represent the most important obstacle for worldwide implementation of fast diagnostic protocols. Therefore,
the authors added a paragraph with a corresponding illustration proposing how to facilitate the diagnostic process
by collection of blood at fixed intervals of 60 min without
awaiting the report of the first blood draw. This strategy has
the advantage of an optimal implementation of the ESC
0/1 h protocol. On the other hand, many perceive the additional costs and unnecessary blood collection anticipated
in ~ 30% of low-risk patients who could have been ruled out
by a single very low hs-cTn value < LoD at presentation as a
relevant disadvantage of such a recommendation [15].
Deferred use of gender‑, age‑ and other
comorbidity‑adjusted diagnostic cutoffs
There is an ongoing discussion on the importance of gender-,
age-, or comorbidity-adapted decision cutoffs [16]. Beyond
doubt and supported by findings from sophisticated cardiac
imaging and cardiac function tests [17], hs-cTn concentrations were found to be lower in healthy women than in men
resulting in a lower 99th percentile upper limit of normal
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(ULN) in women [18]. Likewise, concentrations increase
with advancing age due to age-related subclinical comorbidities even in the absence of objective cardiovascular morbidity or renal impairment [19]. Since symptomatic patients
presenting to an ED are usually older than the average age in
healthy reference populations and are rarely healthy, there
is a debate around the usefulness of a general uniform 99th
percentile ULN. Concentrations of hs-cTn increase with age
and comorbidities decreasing the numbers of patients with
hs-cTn concentrations below the 99th percentile ULN on
admission [20]. Hence, use of a low diagnostic threshold at
the uniform 99th percentile is associated with a very high
sensitivity but low clinical specificity and positive predictive
value. The 4th Universal Definition of Myocardial Infarction
(UDMI) recommended the use of sex-specific upper reference limits (URL, 99th percentiles) and the ESC endorsed
the 4th UDMI [21]. Thus, the ESC 2020 Guidelines [1]
should recommend using different 99th percentiles cutoffs
for men and women. Surprisingly, this it is not the case.
The authors justify this discrepancy between actual ESC
documents with their clinical experience that a “mixture”
of different ULN will confuse the clinicians’ judgement.
Although, the 4th version of the UDMI [21] advocates the
use of serial troponin measurements to discriminate chronic
from acute myocardial injury, not all women having small
hs-cTn increases, who are evaluated with a sex-independent
ULN, may be correctly classified. While this issue may not
be relevant for hs-cTnT [22] and some hs-cTnI assays, previous trials found a relevant diagnostic and prognostic reclassification in women with the Abbott Architect hs-cTnI
assay [23]. With this assay, the difference between men and
women is nearly two times larger than for hs-cTnT. Thus,
the actual NSTE-ACS guidelines are in a partial conflict
with 4th version of UDMI and might disadvantage women.
Increasing importance of high‑sensitivity point‑of‑care
troponin tests with designation for rule out
Until recently, point-of-care (POC) tests were recommended
only in settings where central laboratory assays were not
available, or when turn-around-times (TAT) exceeded
45–60 min. Due to an insufficient analytical sensitivity and
precision of POC technologies, cTn testing on POC devices
used to be utilized as an aid for rule-in of a NSTEMI, but
its use for a reliable rule out of NSTEMI was discouraged
[24]. The LSI Medience Pathfast hs-cTnI assay (formerly
Mitsubishi Pathfast) meets high-sensitivity criteria [25],
received approval by the FDA for use in clinical laboratory
or POC settings [26], has been validated for the ESC 0/1 h
protocol [27], and is also recommended in the 2020 ESC
guidelines [1]. In perspective, several reports indicate a

similar performance of other POC hs-cTnI tests and suggest
that these assays could emerge as alternatives to centralized
laboratory hs-cTn testing in the near future [27–30]. The
shorter TAT with POC testing makes this technology more
appealing as many patients can have AMI excluded at presentation or within 1 h.
However, several shortcomings should dampen the enthusiasm about POC testing including lack of evidence, despite
the existing publications, that POC systems truly work in a
real-world clinical practice when tests are run 24 h/7 days
by non-laboratory personnel and using whole blood as material. In addition, the effect of analytical issues has not been
addressed completely so far [29].
Finally, it is important to indicate that the list of available
POC troponin assays is incomplete regarding cutoffs and
concentration changes for several new hs-cTnI assays using
the ESC 0/2 h protocol, and information on commercially
available assays is not updated since it maintains the Singulex assay that it is not operational since 1 year.
New definition for high‑sensitivity designation of cardiac
Troponin assays
After the introduction of cTn assays with improved analytical sensitivity and precision, it became apparent that there
were no agreed upon criteria to define the high-sensitivity
designation. The scorecard criteria proposed by Fred Apple
were reasonable as they combined analytical and clinical
criteria [31]. Accordingly, cTn assays were attributed a hscTn designation if they were able to measure cTn at or below
the 99th percentile value of a healthy reference population
with a total imprecision of less than 10% CV, and were able
to detect cTn in at least 50% of healthy individuals. This suggestion was refined by the International Federation of Clinical Chemistry (IFCC) and Laboratory Medicine Task Force
on Clinical Applications of Bio-Markers (IFCC TF-CB)
introducing the requirement to measure cTn concentrations
above the limit of detection in 50% of men and women [32].
Unfortunately, reference populations with a sample size
large enough to allow the calculation of sex-specific cutoffs
are sparse, and many manufacturers have no access to appropriately sized sample banks. Now, the 2020 ESC guidelines
[1] softened the IFCC criteria by eliminating the requirement for detection of cardiac troponin in at least 50% of both
genders, presumably to facilitate the faster implementation
of commercially available cTn assays with high-sensitivity
designation [1]. Only in the POC paragraph a 50 to 95%
rate of measurements above the LoD is briefly mentioned.
However, at that point, a discussion should be initiated about
standardized criteria for the validation of new hs-cTn assays
and diagnostic algorithms before their entry in Guidelines.

13

Clinical Research in Cardiology

Controversies and uncertainties
1. 2020 ESC Guidelines on NSTE-ACS recommend the use of the ESC 0/2 hour algorithm with
blood sampling at 0 hour and 2 hours, if a hs-cTn test with a validated algorithm is
available – as an alternave to the ESC 0 hour/1 hour algorithm (Class IB)

The 2020 ESC Guidelines recommend a novel ESC
0/2 h-algorithm as the preferred alternative to the ESC
0/1 h-algorithm in the early triage of suspected acute myocardial infarction This algorithm is similar to the ESC 0/1 h
algorithm and uses distinct thresholds for baseline concentrations and change value for a re-testing at 2 h. The algorithm contains a strategy for immediate rule out based on
a single low hs-cTn concentration at baseline and requires
serial measurements two hours apart. While the two strategies combined in the novel algorithm have been derived and
validated separately, the entire ESC 0/2 h algorithm has not
been validated, yet. Distinct to the Accelerated Diagnostic
Protocol (ADP) 0/2 h protocol, the ESC 0/2 h algorithm does
not require a clinical score, i.e. the TIMI score to achieve an
acceptable safety.
Five publications [33–37] were discussed to support this
recommendation. Neumann et al. [33] prospectively evaluated individual patient-level data from 15 studies including
23,327 patients who presented to the emergency department with suspected acute myocardial infarction (AMI).
The validation cohort on 13,047 patients included a 2-h hscTn-based ADP algorithm from Australia (summarized as
ADAPT-BSN) and New Zealand (summarized as ADAPTCH). Thus, while this study nicely supports the usefulness
of fast diagnostic protocols with repeat sampling within
210 min, there is no obvious reason to restrict the recommendation to the ESC 0 h/2 h protocol and not to extend the
recommendations to the hs-cTn-based 2-h ADP protocol,
as well. Boeddinghaus et al. [34] compared the diagnostic
accuracy, quantified by the area under the receiver operating
curve (AUC), of the Siemens-hs-cTnI-Centaur assay versus
the two established hs-cTn assays (Roche-hs-cTnT-Elecsys,
Abbott-hs-cTnI-Architect). In addition, the investigators
developed a diagnostic algorithm for the new Siemens Centaur assay for the ESC 0 h/1 h and ESC 0 h/2 h protocols.
The derivation cohort for the hs-cTnI Siemens Centaur ESC
0 h/1 h algorithm was randomly selected among patients
with an available blood sampling set at 0 h and 1 h. For
the derivation set for the ESC 0 h/2 h algorithm patients
were randomly selected in a 2:1 ratio to ensure a sufficient
number of patients. Validation was executed in the same
cohort but not in an independent external cohort. Optimal
thresholds for rule out were selected to allow for maximal
sensitivities and negative predictive values (NPVs) of 99%
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and were not based on package insert-specified thresholds.
Optimal thresholds for rule-in were obtained based on a classification and regression tree (CART) analysis targeting a
minimal positive predictive value (PPV) of 70%. While the
performance of the ESC 0 h/1 h and ESC 0 h/2 h algorithm
was studied for the new hs-cTnI Siemens Centaur in the
derivation and validation set, with the Roche hs-cTnT and
Abbott Architect hs-cTnI serving as reference, it was not
within the scope of this study to compare the ESC 0 h/1 h
and ESC 0 h/2 h algorithms. Thus, both algorithms have not
been compared directly.
Reichlin et al. [35] analyzed the diagnostic accuracy of
absolute delta (Δ) and relative (%) changes of cTn among
836 patients presenting to the emergency department with
symptoms suggestive of AMI. Blood samples for the determination of high-sensitive cTnT and Siemens cTnI ultra
were collected at presentation and after 1 and 2 h. The AUC
for diagnosing AMI was significantly higher for 2-h absolute (Δ) versus 2-h relative (%) cTn changes. The authors
concluded that absolute changes of cTn levels have a significantly higher diagnostic accuracy for AMI than relative
changes and seem, therefore, to be the preferred criteria to
distinguish AMI from other causes of cTn elevations.
Hence, neither the performance of hs-cTn in general nor
the relative performance of the ESC 0 h/1 h versus the ESC
0 h/2 h was evaluated in this publication, raising the question why this article was referenced in the Guidelines to
support a 0 h /2 h algorithm as an alternative to the ESC
0 h/1 h algorithm. Boeddinghaus et al. [36] developed an
algorithm for the use of the Abbott Architect hs-cTnI assay
in 1,435 patients using a derivation cohort from the Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) study, and was consecutively validated for
diagnostic accuracy in 1,194 patients from the 2-h Accelerated Diagnostic Protocol to Assess Patients With Chest
Pain Symptoms Using Contemporary Troponins as the Only
Biomarker (ADAPT) trial. Optimal thresholds for rule out
were selected to allow for a maximal diagnostic sensitivity and NPV of 99%. Optimal thresholds for rule-in were
selected to allow for the highest diagnostic specificity and
positive predictive value (PPV). Diagnostic sensitivity and
NPV were 98.7% and 99.7% for rule out, specificity and PPV
were 97.4% and 82.2% for rule-in, respectively. Thirty-day
survival was 100% for rule out patients in both cohorts. This
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study provides evidence supporting the safe use of a 0 h/2 h
algorithm based on the Roche hs-cTnT and the Abbott
Architect hs-cTnI assays. The algorithm was validated in
an external independent cohort showing comparable performance. As such this article is valid to support the usefulness
of 0 h/2 h algorithm, but does not provide information on its
performance relative to the ESC 0 h/1 h or the ESC 0 h/3 h
algorithms.
Nestelberger et al. [37] investigated an algorithm for the
use of the ACCESS hs-cTnI (Beckman Coulter). The authors
used 1,131 patients of a derivation cohort from the APACE
study. The algorithm was consecutively validated for diagnostic accuracy externally in 1,280 patients from two studies using similar inclusion and exclusion criteria, namely
the Accelerated Diagnostic Protocol to Assess Patients with
Chest Pain Symptoms Using Contemporary Troponins as the
Only Biomarker (ADAPT) and the Improved Assessment
of Chest Pain Trial (IMPACT). Findings in the derivation
and validation studies demonstrated safety and efficacy of
the hs-cTnI-Access 0/2-h algorithm for rule out or rule-in
of AMI. This study confers evidence for the usefulness of
a 0/2 h algorithm but does not provide information on the
relative performance of the 0/2 h algorithm compared to
ESC 0 h/1 h or ESC 0 h/3 h algorithm.
Thus, consistent with 2020 ESC NSTE-ACS Guidelines
[1], overall evidence supports a class IB recommendation
for the ESC 0 h/2 h algorithm with the advantage that findings from observational studies were validated in external
independent cohorts. Unfortunately, evidence supporting
the effectiveness and safety of hs-cTn-based ADP protocols
was not appropriately indicated leading to a disadvantage
of the latter.
Underappreciation of the hs‑cTn based ADP 0/2 h
algorithms
Algorithms were developed based on hs-cTn results at
admission and 2 h to further shorten evaluation time. These
algorithms apply data-driven cutoffs not reflecting assay performance or biological plausibility, and incorporate specific
(Δ) values. However, these alternative fast diagnostic strategies were not recommended as an alternative to the ESC
0 h/1 h or ESC 0 h/2 h protocols although there is abundant
scientific evidence to support a class IB recommendation for
ADP protocols, as well. Supportive evidence for the diagnostic performance of ADPs using hs-cTn with sampling
at admission and 2 h is summarized in a review article by
Eggers et al. [38].
The ADAPT trial investigated an ADP that was built
on a TIMI risk score of 0, non-ischemic ECG, and nonincreased cTn results at admission and at 2 h [39]. In studies using hs-cTn assays, the ADAPT-ADP provided a 100%
sensitivity regarding 30-day MACE, but only 19.6–32.3%

of the patients qualified for rule out. Modifying the ADP by
including a TIMI score of 1 increased the rule out group to
29.8–41.5% at the expense of lower prognostic sensitivities
(94.1–100%). Another critical point of this study is that no
events occurred at all and, therefore, this study could have
had significant selection bias or an error in the design.
The Emergency Department Assessment of Chest Pain
Score (EDACS) integrates information on weighted variables (demographics, risk factors, symptom characteristics)
[40]. The EDACS-ADP uses an EDACS score of 16 points,
a non-ischemic ECG, and normal cTn concentrations at
admission and at 2 h to identify patients eligible for early
rule out. In a randomized head-to-head comparison with the
ADAPT-ADP (n = 558), the EDACS-ADP pathway has been
shown to identify more low-risk patients (47.7% vs 32.3%)
while providing high safety with a sensitivity of 100% for
survival. [41]. A randomized trial on 544 patients with suspected ACS randomized patients to a rapid diagnostic pathway or a standard care to test the effectiveness defined as
discharge from hospital within 6 h without a major adverse
cardiac event occurring within 30 days [42]. The impact
of this randomized trial [42] on the strength of recommendation class and level of evidence was not appropriately
addressed by the 2020 ESC Guidelines [1].
Wildi K et al. [43] directly compared the ADP 2-h protocol against the ESC 0/2 h protocol only for rule out (but not
for rule-in) in two independent cohorts, namely the APACE
study and the ADAPT trial. Both algorithms provided
very high and comparable safety as quantified by the NPV
and sensitivity for AMI and major adverse cardiac events
(MACE) at 30 days in patients triaged toward rule out. The
percentage of patients triaged toward rule out was significantly lower with the 2-h ADP (36–43%) versus the ESC 2-h
algorithm (55–68%) with both assays and in both cohorts
(p < 0.001). The sensitivity of the 2-h ADP was higher for
30-day major adverse cardiovascular events. The ESC 2-h
algorithm was more efficient but not all patients ruled out for
AMI by this algorithm were appropriate candidates for early
discharge. Accordingly, the authors concluded that the 2-h
ADP seems superior in the selection of patients for early discharge from the ED. Although this study cannot be regarded
as appropriate for a recommendation of effectiveness across
the entire diagnostic spectrum of suspected ACS, at least the
favorable findings on the 2-h hs-cTn ADP algorithm raise
the question why these study findings were excluded from
the evidence-based recommendation process.
In summary, the substantial evidence supporting hs-cTnbased ADP protocols including the presence of positive findings from a randomized trial was not appropriately reflected
by the 2020 ESC NSTE-ACS Guidelines [1]. Neither the
existing evidence nor findings from a randomized trial [42]
supporting a hs-cTnI based 2-h ADP was reported. In addition, the Guidelines did not mention unfavorable findings
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with ESC 0/2 h algorithm compared to the 2-h ADP from
a study that directly compared strategies, with a restricted
focus on rule out alone [43].
Thus, it appears that almost all recommendations and
protocols have been derived from evidence based on the
APACE registry while other alternative evidences were
largely omitted.

both hs-cTnT and hs-cTnI. The relevance of this article for
the ESC recommendation is controversial for two reasons:
(a) the investigators focused on the rule-out part only, but
did not evaluate the complete diagnostic process that incorporates rule-in AND rule out, as well as an observational
zone that is exclusive to the ESC 0 h/1 h algorithm; (b)
because the significant difference between ESC 0 h/1 h and

2. 2020 ESC Guidelines on NSTE-ACS recommend to consider (Class IIa) a rapid rule-out and
rule-in protocol with blood sampling at 0 hour and 3 hour, if a high-sensivity (or sensive)
cardiac troponin test with a validated 0 hour/3 hour algorithm is available – as an
alternave to the ESC 0h/1 hour algorithm

The 2015 ESC NSTE-ACS Guidelines [2] recommend
use of the ESC 0 h/3 h algorithm based on several large
observational studies that conferred evidence beyond doubt
on the superiority of the ESC 0 h/3 h algorithm over the
standard protocol with blood sampling at 0 h and 6–9 h in
the absence of a high-sensitivity cardiac troponin assay.
Four publications are now cited to support the assigned
class IIa (LOE B) recommendation, i.e. to prioritize the
ESC 0hour/1 h algorithm over the ESC 0 h/3 h protocol
[44–47]. These references are likely to fuel a controversial
debate as they do not unequivocally support the assigned
class of recommendation. The article by Wildi et al. [44]
evaluated the performance of the ESC 0 h/3 h protocol using
four different high-sensitivity cTn assays. The 3-h rule-out
protocol correctly diagnosed 99.9% (95% CI 99.1–100%),
99.5% (95% CI 98.3–99.9%), 100% (95% CI 98.1–100%),
and 100% (95% CI 98.2–100%) of early presenters (< 6 h
from chest pain onset) supporting a high recommendation
class for the ESC 0 h/3 h over the “old” ESC standard protocol with blood sampling at 0 h and re-testing after 6–9 h.
However, this article does not provide any data that compare
the ESC 0 h/1 h or ESC 0 h/2 h protocols with the ESC
0 h/3 h protocol. Hence, citation of this article in this context
seems inappropriate.
Badertscher et al. [45] directly compare the efficacy and
safety of the ESC 0 h/3 h algorithm with the ESC 0 h/1 h
algorithm for rule out of a MI using the Roche hs-cTnT and
the Abbott Architect STAT hs-cTnI assays. The negative
predictive values for the ESC 0 h/1 h algorithm are significantly lower than those for the ESC 0 h/3 h protocol using
the Abbott Architect hs-cTnI. The NPVs for the ESC 0 h/3 h
protocol are similar with the ESC 0 h/1 h algorithm when
using the hs-cTnT assay. A significantly higher proportion
of patients qualifying for rule out was demonstrated for the
ESC 0 h/1 h algorithm versus the ESC 0 h/3 h protocol with
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ESC 0 h/3 h is restricted to a higher rate of patients in the
rule-out pathway, and at least for the hs-cTnT assay a similar
performance for the safety of rule out is demonstrated.
The third article by Chapman et al. [46] compared the
diagnostic performance of three rapid diagnostic protocols,
namely the High-STEACS pathway, the ESC 0 h/1 h, and
the ESC 0 h/3 h protocols in a retrospective analysis. All
three protocols were compared regarding sensitivities, specificities, negative and positive predictive values using the
new Atellica IM hs-cTnI assay (Siemens Healthineer) from
frozen samples. Briefly, the NPVs of all three strategies were
between 98 and 99.5%, highest for the High-STEACS pathway and lowest for the ESC 0 h/3 h protocol. Sensitivities
were considerably lower for all three strategies ranging from
90.8 to 92.2% for the ESC 0 h/3 h and ESC 0 h/1 h to 98%
for the High-STEACS pathway. Specificities and PPVs were
disappointingly low for all pathways, with the exception of
a specificity of 98.2% for the ESC 0hour /1 h protocol. This
comparative study was limited by three shortcomings: (a) it
was retrospective evaluation; (b) the cutoffs of 3 and 5 ng/L
for new Atellica IM hs-cTnI assay (Siemens) were transferred from a different study using hs-TnI concentrations
measured by the Abbott Architect systems; (c) all measurements were conducted by Siemens Healthineers, and thus
relevant conflicts of interest exist, which should preclude
this study from being used in the Guidelines.
The fourth article by Chapman et al. [47] compared
the performance of the High-STEACS pathway with the
ESC 0 h/1 h protocol on 1,218 patients with suspected
ACS. Briefly, this study is interesting but does not add any
information on the superiority of the ESC 0 h/1 h protocol
because this study compared the High-STEACS pathway,
with blood sampling at 0 h and 3 h with the ESC 0 h/3 h
protocol.

Clinical Research in Cardiology

3. The 2020 ESC Guidelines do not recommend to rou nely measure addi onal biomarkers
(class IIIB) such as h-FABP or Copep n, in addi on to hs-cTn – for ini al diagnos c
purposes.

This class IIIB recommendation is most critical as it
implies that other diagnostic biomarkers perform inferior
or might even harm. Therefore, such a recommendation
class should be supported by robust evidence, particularly
when previous ESC guidelines [2] recommended using additional biomarkers, and because neither hs-cTn assays nor
fast diagnostic protocols have been implemented broadly,
at the moment [14].
Copeptin for instant rule out of MI
Copeptin is the molecule including the 39 aa carboxy-terminal (CT) sequence of the pro-vasopressin molecule and it
is considered a non-specific biomarker with rapid increase
in AMI in blood while cTn or hs-cTn levels are still normal,
termed the “troponin-blind period” [54]. CT pro-vasopressin
(Copeptin) as a marker of vasopressin reflects the immediate physiological response to arterial under-filling in AMI,
when the cardiac output decreases in minutes after epicardial
vessel closure. Commonly, this phenomenon is addressed as
“cardiovascular stress”. The 2020 ESC NSTE-ACS guidelines [1] suggest that low Copeptin concentrations below
the decision cutoff could improve the negative predictive
value (NPV) of cTn for ruling out patients presenting early
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after symptom onset when cTn is not elevated in the first
blood sample [1]. Conversely, a positive Copeptin while
cTn or hs-cTn is below the 99th percentile URL suggests a
strict serial troponin strategy. Despite increasing evidence
[48–51] supporting that Copeptin accelerates the rule out
of MI when combined with a hs-cTn assay (Fig. 1), ESC
guidelines endorse the use of Copeptin as an alternative only
when sensitive or high-sensitivity cardiac troponin assays
are not available. This contrast with 2015 ESC Guidelines
[2] that state that “Copeptin may have some added value
even over high-sensitivity cardiac troponin in the early rule
out of MI”. Recently, Wildi et al. [59] reported on the performance of 14 rule-out strategies in patients admitted with
suspected NSTE-ACS. A dual marker strategy (DMS) combining Copeptin with hs-cTn was associated with the worst
performance amongst all strategies for rule out in terms of
sensitivities and NPVs, and was associated with the highest
event rates within 90 days. However, it is important to indicate that DMS was tested retrospectively across the entire
study cohort and did not exclude high-risk patients, as recommended [48, 49]. A substudy from TRAPID-AMI [55]
investigating the role of Copeptin combined with hs-cTn
elegantly demonstrated that exclusion of high-risk patients
resulted in 100% sensitivity and 100%NPV, without any
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Fig. 1  Accumulating evidence supporting the usefulness and added value of Copeptin in addition to cTn or hs-cTn over time
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Table 1  Literature claiming insufficient evidence for added value of Copeptin and h-FABP in addition to hs-cTn for the initial diagnosis
(Adapted from Möckel ref#[82])
Authors

Marker

Results

Boeddinghaus et al. 2017 [52]

Copeptin, hs-cTnT, hs-cTnI

Hillinger et al. 2015 [53]

Copeptin, hs-cTnT at 0 and 1 h
(off-label)

PPV (off-label for copeptin) better Retrospective from APACE,
with 1 h troponin
n = 1356
NPV 100% in copeptin and hs-TnT Retrospective from APACE 2006–
negatives
2011, highly selected, n = 941,
explorative study
Opinion paper
NPV 100% in low-risk cohort
TRAPID-AMI substudy, n = 922
(label use)
Retrospective from APACE
NPV in early presenters:
2009–2011, n = 2183 and n = 328
Copeptin + hs-TnT 96%
from Luzern; n = 2000 analysed
hs-TnT alone: 92.9%
Independent prognostic value
Retrospective from OPUS-TIMI-16;
(death and MACE)
n = 2287

Mueller et al. 2018 [54]
Copeptin
Mueller-Hennessen et al. 2019 [55] Copeptin, hs-cTnT
Stallone et al. 2016 [56]

Copeptin, hs-cTnT

O‘Donoghue et al. 2006 [57]

h-FABP

adverse outcome event. Accordingly, it does not become
evident why the previously assigned recommendation was
not expended but rather downgraded. Besides, the class III
recommendation is contradicted as the Guidelines itself state
that Copeptin can be used in special situations (page 13,
right column).
Articles cited in support of an inferior performance
of Copeptin in combination with hs‑cTn
In the 2020 ESC NSTE-ACS Guidelines, six references
[52–57] are listed to support a class IIIB recommendation.
These references are summarized in Table 1.
Most importantly, all referenced articles do not support an
inferior diagnostic performance, and none of these articles
indicate potential harm. In particular, the article by Boeddinghaus et al. [52] does not qualify for referencing because
it focuses on the PPV of Copeptin which represents an offlabel use of Copeptin in the setting of a suspected ACS.
Among the four possible combinations, only the combination of normal or undetectable Copeptin and cTn/hs-cTn
concentrations serve for rule out. In addition, the instant
rule-out protocol should not include patients at high risk. In
addition, previous studies were confounded by questionable
use of statistical methods [53, 54, 58, 59]. First, comparison
of non-independent groups, e.g. the same patients assessed
for the performance of the 0-h versus 0-h/1-h protocol,
should be tested with the McNemar instead of Pearson’s
Chi2 test as the same population is tested repeatedly. Second,
the evaluation of a rule-out test should be restricted to the
assessment of sensitivities and NPVs but should not include
specificities and PPV. Accordingly, C-statistics that assess
the discriminatory ability of a continuous biomarker across
the entire diagnostic spectrum, i.e. balance sensitivity and
specificity are not appropriate.
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The article by Hillinger [53] which derives data from the
same APACE registry, demonstrates a NPV for Copeptin in
combination with hs-cTnT of 100% and hence at least cannot
support the claim of an inferior performance compared to
the ESC 0 h/1 h algorithm.
The third article is a current opinion paper from the ESC
Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association [54]. This educational paper
does not opt against the measurement of Copeptin in addition to cTn or hs-cTn. Literally, it is stated that the added
value of Copeptin to hs-cTn is less obvious, at the time of
drafting that document. It is also stated that while studies
found a marginal increase of overall diagnostic accuracy as
quantified by the AUC, there was a statistically significant
and clinically relevant increase of the NPV from 96 to 99%.
The fourth article by Mueller-Hennessen et al. reports on
the diagnostic and prognostic performance of Copeptin in
addition to hs-cTnT in a substudy from the TRAPID-AMI
trial [55]. Looking at the overall study cohort, a dual marker
strategy (DMS) was associated with higher sensitivity (94.8
vs 89%) and negative predictive value (98.3 vs 97.4%) compared to the standard protocol based on the 99th percentile. After exclusion of high-risk patients as indicated by a
modified HEART Score > 3 points, sensitivity and NPV of
DMS increased to 100% for both, with no death occurring at
30 days. Hence, this TRAPID substudy rather supports the
usefulness of DMS but definitely does not indicate potential
harm. The fifth article by Stallone et al. [56] reports on findings from the APACE registry on 2,511 patients with suspected ACS presenting early after symptom onset. Of those,
only 2000 patients were analyzed. In early presenters, sensitivities impressively increased from 74.5 to 91.2% and negative predictive values from 92.9 to 96% by the additional
use of Copeptin on top of hs-cTnT. Thus, this article rather
supports the usefulness of Copeptin in early presenters,
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presumably by overcoming the troponin-blind interval in
the early hours after onset of myocardial infarction.
Finally, the article by Donohue et al. [57] reports findings from the randomized “Orbofiban in patients with
unstable coronary syndromes-thrombolysis in myocardial
infarction-16 (TIMI-OPUS-16) trial on 2,287 patients. This
paper that was published 2006 and thus many years before
the introduction of hs-cTn, demonstrated an independent
prognostic value for heart-type fatty acid binding protein
(h-FABP) for prediction of death and major cardiac events
but does not confer any information on the diagnostic value
of h-FABP or other additional biomarkers.
Articles in favor of a DMS combining Copeptin
with high‑sensitivity cardiac troponin
In addition to these controversies, numerous articles that
confer incremental information on the added value of
Copeptin to cTn and particularly to hs-cTn are not mentioned, at all (Fig. 1). These articles include the following
investigations:
The Biomarkers in Cardiology-8 (BIC-8) trial [48], an
international multicenter intervention trial on 902 patients
that randomized patients with suspected ACS and low-tointermediate risk to either the standard algorithm or the
experimental DMS algorithm in the presence of a normal
cTn/hsTn and a normal Copeptin [48]. This study demonstrated reduced length of stay in ED, higher discharge rates
and importantly safety of discharge based on DMS that was
as safe as discharge based on a standard diagnostic protocol.
Of note, no death occurred in the experimental DMS arm at
30 days. This study was already presented during a Highlight
Session at the 2014 ESC and corroborates the usefulness
and safety of DMS based on a randomized trial design. In
this RCT, Copeptin was combined with hs-cTn assays in
about 2/3 of all patients. To generalize findings to clinical
routine, a multicenter prospective observational trial (proCORE) was conducted in 18 emergency departments in nine
European countries enrolling 2,451 patients with suspected
ACS [49]. This registry confirmed the safety of the ruleout strategy with DMS with a significantly lower all-cause
mortality than standard of care pathway with serial troponin
measurements. Of note, there was only one fatality case in
the DMS arm who died from cancer. Therefore, it is miraculous, why the RCT [48] confirmed by a multicenter registry
was not considered for evidence at all. In addition, a health
economic substudy [50] from the BIC-8 RCT demonstrated
cost effectiveness using DMS versus standard diagnostic
strategy in patients presenting with suspected ACS. Finally,
a pooled analysis [51] using data on patient level was used
aggregating data from 10,329 patients with suspected ACS
who had received a rule out of MI using DMS or a standard

troponin-based strategy. A sub-analysis of 3487 patients
evaluating the hs-TropT from Roche showed a higher applicability with the DMS to rule-out patients when compared
to a single marker strategy with hs-cTnT for instant rule out
at admission. All four important publications [48–51] were
not appropriately addressed in the 2020 ESC Guidelines.
Not referring to important evidence yields an unbalanced
recommendation.
Overemphasis on hs‑cTn assays despite low global
implementation of hs‑cTn and fast protocols
The 2020 ESC guidelines continue to recommend the routine use of Copeptin as an additional biomarker for the early
rule out of MI only in “the increasingly uncommon setting
where hs-cTn assays are not available”. However, such a
recommendation has no practical consequence in the light
of the slow rate of global adoption of hs-cTn assays and fast
protocols [14].
CK‑MB for the diagnosis of a re‑infarction,
and myosin‑binding protein C for the early rule
out of NSTEMI
When hs-cTn assays are not available, the ESC guideline
proposes as alternative biomarkers CK-MB for the diagnosis
of a re-infarction, and Copeptin or myosin-binding protein
C for the early rule out of NSTEMI. These proposals merit
some comments.
CK‑MB for re‑infarction diagnosis A re-infarction is defined
as any acute myocardial infarction (AMI) occurring within
28 days of an incident or recurrent MI [60]. Thus, based on
the release pattern of cTn and CK-MB, any MI occurring
after 7–10 days of a previous MI will be detected more sensitively and specifically by any cTn method than by CK-MB.
The ESC Guidelines [1] refers to the use of CK-MB for
early recognition of an MI occurring, supposedly, during the
time interval in which cTn is still elevated owing to the first
MI [1]. After any AMI, CK-MB values decrease to normal in
48–72 h, whereas cTn can remain elevated up to 7–10 days
after the AMI. However, the guidelines do not take into
account that CK-MB can be released by skeletal muscle in
MI patients by several causes leading to loss of diagnostic specificity and that any it does not exist an unanimous
value of the percent or absolute increase/fall that will define
a significant CK-MB elevation after a previous MI. Of note,
regardless the limited potential use of CK-MB as alternative
for re-infarction the guidelines did not distinguish between
CK-MB measured as catalytic activity or mass concentration. In addition, even when using contemporary methods
for its measurement, cTn can detect re-infarctions occurring
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in the following 48-96 h after a previous MI using serial
measurements [61].
Very recently, the ESC Study Group on Cardiac Biomarkers of the Association for Acute Cardiovascular Care
published a current opinion article summarizing the reasons
why CK-MB is no longer needed and suggests to eliminate
CK-MB from the menu of biomarkers available for use in the
evaluation of patients cardiovascular disease [62].
Cardiac myosin‑binding protein C for earlier NSTEMI rule
out Cardiac myosin-binding protein C is a specific cardiac
isoform (C-protein, MYBPC3, cMyBP-C, cMyC) which
myocardial abundance is at least two times that of cTn. After
an AMI, septal hypertrophy ablation or coronary artery
bypass surgery, cMyC concentrations increase more rapidly
and higher than those of cTn [63]. When measured with a
so-called high-sensitivity immunoassay, its sensitivity and
specificity for AMI diagnosis were comparable to that of
hs-cTn [64], and the best cMyC diagnostic performance was
observed in patients who presented very early after symptoms (< 3 h) [65]. Unfortunately, the methods available for
cMyC measurement are only partly automatable and require
several hours to the result and this fact precludes its use for
the Guidelines proposed purpose.

The second paper by Balmelli et al. [67] examined and
compared the diagnostic and prognostic performance of
selected cardiac biomarkers in 420 women and 827 men
with suspected ACS recruited in the APACE study. Regarding the prognostic performance of selected biomarkers, the
combination of cTnT and Copeptin outperformed cTnT
alone, both in women and men. This study supports the
additional use of Copeptin added to cTn but cannot be used
to recommend against the use of Copeptin. The third paper
based on the “Copeptin Helps in the early detection Of
Patients with acute myocardial Infarction” (CHOPIN) trial
[68] investigated the diagnostic performance of Copeptin
added to conventional cTn in suspected ACS presenting
to an ED within 6 h of pain onset. A total of 1,967 patients
with chest pain were enrolled at 16-sites study. The primary endpoint was diagnosis of AMI. The AUC of troponin alone in the first blood sample taken in the ED was
0.86, and increased to 0.97 by adding Copeptin. Using this
double marker approach, a negative troponin and Copeptin < 14 pmol/l at presentation allowed AMI to be ruled out,
with an NPV > 99% [68]. A second important result of the
CHOPIN study relates to the prognostic role of Copeptin
for outcome prediction at 30 days (n = 13 deaths; survival
rate 99.3%), Copeptin was associated with adverse outcome,
with a Chi-square test of 29.2 and a c-index of 0.872, and

4. The ESC NSTE-ACS Guidelines recommend against the measurement of addional
biomarkers such as mid-regional pro-A-type natriurec pepde, high-sensivity C-reacve
protein, mid-regional pro-adrenomedullin, GDF-15, Copepn, and h-FABP for roune risk
or prognosis assessment.

The recommendation against the routine use of additional
biomarkers is based on three citations that exclusively refer
to Copeptin but not to the other listed biomarkers [48, 66,
67].
The first citation refers to the Biomarkers-in-Cardiology-8 (BIC-8) trial [48], a randomized interventional trial
that randomly assigned patients to either standard of care or
to the experimental Copeptin arm where patients with negative troponin and Copeptin values at admission were eligible
for discharge after final clinical assessment. Among the 902
low- to intermediate-risk patients, early discharge after clinical assessment in the Copeptin and Troponin negative arm
was as safe as the standard diagnostic algorithm based on
serial cTn or hs-cTn measurements with the 99th percentile as diagnostic threshold [48]. The testing of Copeptin is
complementary to cTn and as such this study rather supports
the additional measurement of Copeptin but definitely does
not imply harm by a dual biomarker strategy. In a secondary analysis, Copeptin shows significant and independent
prognostic values over hs-cTnT [66].
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cTnI had a Chi-square value of 13.7 and a c-index of 0.828.
Both markers were independent of each other and combining
them provided significant added value (p = 0.01 for added
value of cTnI, p < 0.0001 for added value of Copeptin). The
incremental value was visible until the end of follow-up at
180 days. Hence, the findings from the CHOPIN trial [68]
corroborate the clinical usefulness of a negative Copeptin
in combination with a negative cTn but more importantly
demonstrate added and independent prognostic value for
prediction of outcomes within 180 days after NSTE-ACS.
Additional evidence from observational trials [69–72] and
a meta-analysis [73] have accumulated substantial evidence
for a prognostic role of Copeptin when used together with
a hs-cTn. Von Haehling [71] reported data from 2,700
patients with symptomatic coronary artery disease (CAD),
who either presented with suspected ACS to the ED, or for
elective coronary angiography. The predictive performance
of Copeptin was independent of any other clinical variables
or cardiovascular risk factors, and superior to that of troponin I or other cardiac biomarkers (p < 0.0001). Zellweger
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et al. [74] evaluated 379 patients with diabetes mellitus in a
cohort of 1,991 patients presenting with suspected NSTEACS from the APACE registry. In multivariate Cox analysis,
Copeptin, and hs-TnT were strong and independent predictors of 24-month mortality. Using the dual marker strategy
(Copeptin and troponin) identified two groups of high-risk
patients where 22.5% of the group with hs-cTnT and Copeptin above the cutoff died. The authors conclude that while
Copeptin only slightly improves the early diagnosis of AMI
provided by hs-cTnT, both markers (Copeptin and troponin)
predict long-term mortality accurately and independently of
each other. Potocki et al. [72] reported on 1,170 consecutive patients presenting with suspected AMI and pre-existing
CAD. Copeptin used at a cutoff < 9 pmol/L was a strong and
independent predictor of 1-year mortality, even after inclusion of hs-cTn into the Cox regression model with a HR 4.63
(1.83–11.71). Irrespective of hs-cTn or cTn levels, patients
with low levels of Copeptin had an excellent prognosis compared with patients with raised levels of both Copeptin and

cTn (360-day mortality 2.8–3.6% vs 23.1–33.8%, p < 0.001).
Morawiec et al. [70] reported on 154 patients showing that
the highest event-free survival at 30 days was achieved
in patients stratified with an algorithm that combines hsTnT, a modified HEART Score (mHS) ≤ 3, and Copeptin,
with 100% (95% CI 75.3–100) NPV and 100% (95% CI
96.6–100) sensitivity. Another article by Reiter et al. [75]
based on patients recruited in the APACE study reported
on the diagnostic and prognostic value of biomarkers added
to hs-cTn. In 1,074 patients evaluated for suspected NSTEACS, heart-type fatty acid binding protein (h-FABP) and
Copeptin did not improve the diagnosis of patients but were
found to add independent incremental prognostic information beyond hs-TnT. When adjusted to hs-cTnT levels, age,
sex and cardiovascular risk factors, h-FABP had additional
predictive value regarding mortality (HR 1.023 (95% CI
1.011 to 1.036), p < 0.001) beyond hs-cTnT (p > 0.05). This
was also the case for Copeptin after adjustment (adj. HR
1.004 (95% CI 1.002 to 1.006), p < 0.001).

5. Preferable use of BNP or NT-pro BNP for prognosc assessment in NSTE-ACS

The 2020 ESC Guidelines [1] recommend that concentrations of BNP or NT-pro BNP should be used to gain prognostic information. The class IIa recommendation in favor
of BNP or NT-pro BNP regarding prognostic information
is based on three articles [76–78], a publication from the
Study Group on Biomarkers in Cardiology [76] and two historic original publications dating back to 2001 [77] and 2003
[78], investigating the prognostic value of BNP or NT-pro
BNP added to conventional cTn. More recent findings on
the prognostic value of natriuretic peptides including BNP,

NT-pro BNP, pro ANP or MR-pro ADM when added to an
hs-cTn assay were not mentioned, at all. In the MERLINTIMI 36 trial [69] on 4,432 patients with NSTE-ACS who
were randomized to treatment with ranolazine or placebo,
MR-proADM and MR-proANP and Copeptin were found
to add complementary prognostic information for CV death
and HF in patients with NSTE-ACS performing as well as
or better than BNP, cTnI, ST2, PAPP-A, and MPO (each
p ≤ 0.01).

6. Addional biomarkers do not add but marginal informaon in risk assessment to the
GRACE score or BNP/NT-pro BNP.

Recommendation of 2020 ESC Guidelines [1] on the marginal prognostic benefit of natriuretic peptides when added
on top of the GRACE Score. The statement that additional
biomarkers do not add significant but only marginal information for risk assessment to the GRACE risk score is not supported by existing evidence. Von Haehling [71] studied the
role of Copeptin relative to the conventional GRACE Score
(version 1) in a subgroup of 1,385 patients from a catheterization-laboratory cohort comprising 2,700 patients with
symptomatic CAD. They reported a significant added value
when Copeptin was added to the GRACE score compared to

the GRACE score alone (AUC 0.718 vs 0.618, p < 0.00001).
The AUC was higher than the model combining hs-cTnI
Siemens ultra with the GRACE score (AUC 0.718 vs 0.623).
In an early investigation by Widera et al. in 1,122 patients
with NSTE-ACS [79], that used a rigorous derivation/validation study design, GDF-15 was found to considerably add
discriminatory information to the GRACE score (Version
1) with an increase in the AUC from 0.79 to 0.85 for the
combined primary endpoint of death or non-fatal MI (the
endpoint for which the score was developed). Adjustment
of GRACE-predicted risks by GDF-15 led to a substantial
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proportion of patients appropriately being reclassified into
higher or lower risks (a net 31% of the patients without
events were reclassified into lower risk and a net 27% of
patients with events were reclassified into higher risk), an
effect size that can be classified as strong. In another study
comparing the prognostic performance of 9 biomarkers and
the GRACE score (Version 1) in 1,146 patients with NSTEACS [80], GDF-15 (AUC, 0.771), the GRACE score (AUC,
0.749), and NT-proBNP (AUC, 0.745) displayed the greatest
discriminatory strength, and GDF-15 was the single biomarker that added most to the GRACE score. A recent study
in 4,330 patients with NSTE-ACS enrolled in the MERLINTIMI 36 trial [81] using the new clinically available GDF-15
assay supports the conclusion that GDF-15 independently
predicts risk in NSTE-ACS. It should be emphasized that the
added value of biomarkers (including BNP/NT-pro BNP) to
the new GRACE score (Version 2) has not been studied with
the same methodological rigor. The conclusion that “additional biomarkers do not add but marginal information in
risk assessment to the GRACE score or BNP/NT-pro BNP”,
therefore, seems unjustified.
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